TABLE 1.

Antolimab (AK002) completed clinical trials

Disease	Study design	Primary Findings
Eosinophilic Gastritis and/or Gastroenteritis	Phase 2 randomized, double-blind, placebo-controlled (NCT03496571)	• Met all primary and secondary endpoints including significant histologic and symptomatic improvements in EG/EN patients treated with antolimab vs placebo
		• Strong histologic and symptomatic proof of concept in concomitant EoE
Chronic Spontaneous Urticaria (omalizumab-naïve & omalizumab-refractory); Chronic Inducible Urticarias (cholinergic & symptomatic dermographism)	Phase 2a open-label (NCT03436797)	• High response rates in multiple forms of antihistamine-resistant chronic urticaria, including omalizumab-refractory and inducible urticaria
Severe Allergic Conjunctivitis (atopic keratoconjunctivitis, vernal keratoconjunctivitis, and perennial allergic conjunctivitis)	Phase 1b open-label (NCT03379311)	• Substantial reduction of patient-reported ocular symptoms and physician-assessed signs and symptoms
		• Improvements observed in comorbid atopic dermatitis, asthma, and rhinitis
Indolent Systemic Mastocytosis	Phase 1b open-label (NCT02808793)	• Substantial symptom and quality-of-life improvement